CIK 0000906709
- Non-accelerated filer
- Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943134940
- Phone
- +1 415-482-5300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- 4 Open-market sale SVP & Chief Accounting Officer sold 2,363 shares at $10.95 ($25,875)
- 4 Open-market sale President & CEO sold 12,480 shares at $10.95 ($136,656)
- 4 Open-market sale SVP & Chief Commercial Officer sold 4,852 shares at $10.95 ($53,129)
- 4 Open-market sale SVP, COO & CFO sold 7,579 shares at $10.95 ($82,990)
- 4 Grant or award Chief R&D Officer acquired 52,950 shares (grant or award)
- 4 Grant or award SVP & General Counsel acquired 37,800 shares (grant or award)
- 4 Grant or award SVP & Chief Accounting Officer acquired 21,200 shares (grant or award)
- 4 Grant or award President & CEO acquired 126,050 shares (grant or award)
- 4 Grant or award SVP & Chief Commercial Officer acquired 37,800 shares (grant or award)
- 4 Grant or award SVP, COO & CFO acquired 52,950 shares (grant or award)
- 4/A Insider Changes in Ownership
- 4 Open-market sale SVP, COO & CFO sold 24,149 shares at an average $13.10 ($316,391)
- 4 Open-market sale Chief R&D Officer sold 20,869 shares at $13.16 ($274,636)
- 4 Open-market sale SVP & General Counsel sold 6,564 shares at $13.16 ($86,382)
- 4 Open-market sale SVP & Chief Accounting Officer sold 6,741 shares at $13.16 ($88,712)
- 4 Open-market sale President & CEO sold 42,773 shares at $13.16 ($562,893)
- 4 Open-market sale SVP & Chief Commercial Officer sold 6,061 shares at $13.16 ($79,763)
- 4 Grant or award SVP, COO & CFO acquired 40,150 shares (grant or award)
- 4 Grant or award Director acquired 18,360 shares (grant or award)
- 3 Insider Initial Statement of Ownership
Page 7 of 49 · 968 filings